A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma Meeting Abstract
| Authors: | van Herpen, C.; Postow, M. A.; Carlino, M. S.; Kalkavan, H.; Weise, A.; Amaria, R. N.; De Vos, F.; Carvajal, R. D.; Matano, A.; Bhansali, S.; Lam, L.; Yerramilli-Rao, P.; Sosman, J. A. |
| Abstract Title: | A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma |
| Meeting Title: | 18th European Cancer Conference (ECCO 18) |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 Sep 25-29 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S663 |
| Language: | English |
| ACCESSION: | WOS:000361887403138 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(15)30062-9 |
| Notes: | Meeting Abstract: 3300 -- Source: Wos |
